ALRN Fundamental Analysis - AILERON THERAPEUTICS INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ALRN. ALRN was compared to 558 industry peers in the Biotechnology industry. While ALRN seems to be doing ok healthwise, there are quite some concerns on its profitability. ALRN does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALRN had negative earnings in the past year.

ALRN had a negative operating cash flow in the past year.

In the past 5 years ALRN always reported negative net income.

In the past 5 years ALRN always reported negative operating cash flow.

1.2 Ratios

ALRN has a better Return On Assets (-28.06%) than 70.55% of its industry peers.

ALRN's Return On Equity of -30.71% is fine compared to the rest of the industry. ALRN outperforms 78.31% of its industry peers.

		Industry Rank	Sector Rank
ROA	-28.06%
ROE	-30.71%
ROIC	N/A

ROA(3y)-64.32%

ROA(5y)-86.69%

ROE(3y)-74.12%

ROE(5y)-115.87%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALRN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALRN has more shares outstanding

ALRN has more shares outstanding than it did 5 years ago.

ALRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -1.90, we must say that ALRN is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -1.90, ALRN perfoms like the industry average, outperforming 52.73% of the companies in the same industry.

There is no outstanding debt for ALRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.9

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.30 indicates that ALRN has no problem at all paying its short term obligations.

ALRN has a Current ratio of 3.30. This is in the lower half of the industry: ALRN underperforms 60.85% of its industry peers.

ALRN has a Quick Ratio of 3.30. This indicates that ALRN is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of ALRN (3.30) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.3
Quick Ratio	3.3

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ALRN have decreased by -9.65% in the last year.

EPS 1Y (TTM)-9.65%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%32.52%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALRN will show a small growth in Earnings Per Share. The EPS will grow by 2.99% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-11.33%

EPS Next 2Y3.28%

EPS Next 3Y3.7%

EPS Next 5Y2.99%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALRN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y3.28%

EPS Next 3Y3.7%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALRN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AILERON THERAPEUTICS INC

NASDAQ:ALRN (1/10/2025, 8:00:59 PM)

After market: 2.11 0 (0%)

2.11

+0.18 (+9.33%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2024-11-14/amc

Earnings (Next)N/A N/A

Inst Owners31.86%

Inst Owner Change5.96%

Ins Owners0.65%

Ins Owner Change0%

Market Cap45.72M

Analysts85

Price Target13.26 (528.44%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)15.2%

Min EPS beat(2)-5.04%

Max EPS beat(2)35.44%

EPS beat(4)1

Avg EPS beat(4)-320.99%

Min EPS beat(4)-820.61%

Max EPS beat(4)35.44%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-118.18%

EPS NY rev (1m)0%

EPS NY rev (3m)-5.16%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.48
P/tB	4.71
EV/EBITDA	N/A

EPS(TTM)-3.12

EYN/A

EPS(NY)-1.92

Fwd EYN/A

FCF(TTM)-1.29

FCFYN/A

OCF(TTM)-1.29

OCFYN/A

SpS0

BVpS4.39

TBVpS0.45

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-28.06%
ROE	-30.71%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-64.32%

ROA(5y)-86.69%

ROE(3y)-74.12%

ROE(5y)-115.87%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.3
Quick Ratio	3.3
Altman-Z	-1.9

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-9.65%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%32.52%

EPS Next Y-11.33%

EPS Next 2Y3.28%

EPS Next 3Y3.7%

EPS Next 5Y2.99%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-132.47%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-4.33%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-4.33%

OCF growth 3YN/A

OCF growth 5YN/A

AILERON THERAPEUTICS INC (ALRN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens